Sutro Biopharma (STRO) Share-based Compensation (2016 - 2026)

Sutro Biopharma has reported Share-based Compensation for 9 years, with the latest figure at $1.7 million in Q4 2025.

• Quarterly Share-based Compensation fell 72.02% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.4 million (up 2.03% YoY) and the FY2025 annual result came in at $14.0 million, down 43.26% from the prior year.
• Share-based Compensation eased to $1.7 million in Q4 2025 per STRO's latest filing, from $9.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $39.6 million in Q3 2022 and troughed at $374000.0 in Q1 2024.
• A 5-year average of $10.5 million and a median of $6.4 million in 2021 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 98.22% in 2023, then jumped 1477.54% in 2025.
• Over 5 years, Share-based Compensation stood at $6.9 million in 2021, then jumped by 275.21% to $25.8 million in 2022, then plunged by 75.92% to $6.2 million in 2023, then fell by 4.95% to $5.9 million in 2024, then sank by 72.02% to $1.7 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.7 million, $9.4 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.